Evonik expands its formulation capabilities for lipid nanoparticles
Collaboration with KNAUER to streamline and improve the scale-up of LNP formulations
Collaboration with KNAUER to streamline and improve the scale-up of LNP formulations
These results add to the growing body of evidence indicating a single dose of ABRYSVO provides strong immune protection against outcomes caused by RSV
Revenue from operations stood at Rs. 313.4 crore during Q1 FY25
Revolutionary technology will further boost OneSource’s scientific services offerings
GSK and Flagship to jointly fund up to $150 million upfront
Phase III ARANOTE trial met primary endpoint, significantly increasing radiological progression-free survival (rPFS) with NUBEQA plus androgen deprivation therapy (ADT) compared to placebo plus ADT
Acquisition to expand Lilly's immunology pipeline with oral integrin therapies
Globally, colorectal cancer impacts 1.9 million people each year, standing as a leading cause of cancer mortality
Shares and American Depositary Shares of Olink for $26.00 per Share
Subscribe To Our Newsletter & Stay Updated